As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Immuneering, a filing with the SEC revealed that on Tuesday, Director Peter Feinberg bought 291,667 shares of IMRX, at a cost of $15.00 each, for a total investment of $4.38M. Feinberg was up about 46.6% on the buy at the high point of today's trading session, with IMRX trading as high as $21.99 at last check today. Immuneering is trading up about 10.3% on the day Wednesday. This buy marks the first one filed by Feinberg in the past year.
And at Omega Therapeutics, there was insider buying on Tuesday, by Director David A. Berry who purchased 53,082 shares for a cost of $17.00 each, for a trade totaling $902,394. Omega Therapeutics is trading up about 0.7% on the day Wednesday. Bargain hunters can buy OMGA at a price even lower than Berry did, with the stock trading as low as $16.45 at last check today which is 3.2% below Berry's purchase price.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.